目的比较导流杂交基因芯片技术(HybriMax)和实时荧光定量PCR法(FQ-PCR)检测人乳头状瘤病毒(human papilloma virus,HPV)的敏感性。方法收集2010年2月～2011年8月在某院就诊的可疑HPV感染患者356例,行杂交捕获Ⅱ代法(HC-Ⅱ)检测后,随机分为导流杂交基因芯片技术(HybriMax)组和实时荧光定量PCR法(FQ-PCR)组,分别采用HybriMax和FQ-PCR检测,以HC-Ⅱ检测结果作为对照,比较两种方法的敏感性。结果 (1)HybriMax组总阳性率为83.89%,高于HC-II的73.33%(χ2=6.09,P﹤0.05);对13种高危型HPVDNA的检测阳性率分别为75.56%和73.33%,差异无统计学意义(P﹥0.05);而FQ-PCR检测HPVDNA的总阳性率(61.93%)显著低于HC-II法(72.16%),差异有统计学意义(χ2=4.17,P﹤0.05),(2)HybriMax、HC-Ⅱ、FQ-PCR在细胞低度异常者中检测阳性率相似,分别为47.78%,43.31%,43.87%,无统计学差异;在细胞高度异常者中,HybriMax与HC-Ⅱ检测HPVDNA阳性率分别为91.30%和88.96%,两者差异无统计学意义(χ2=0.45,P﹥0.05);而FQ-PCR与HC-Ⅱ检测阳性率为76.19%和90.48%,虽经统计学检验差异无统计学意义,但趋势提示FQ-PCR临床敏感性可能低于HC-Ⅱ。结论 HybriMax技术检测HPVDNA临床敏感性好,且具有同时分型的优势,值得临床推广。 Objective To compare the sensitivity of human papilloma virus (HPV) with HybriMax and real-time fluorescence quantitative PCR (FQ-PCR). Methods 356 cases of suspicious HPV infection in a hospital from February 2010 to August 2011 were collected and detected by HC-Ⅱ hybridization and then randomly divided into HybriMax group And real-time fluorescence quantitative PCR (FQ-PCR) group were detected by HybriMax and FQ-PCR respectively. HC-Ⅱ test results were used as a control to compare the sensitivity of the two methods. Results (1) The positive rate of HybriMax group was 83.89%, higher than that of HC-II 73.33% (χ2 = 6.09, P <0.05). The positive rates of HPVDNA in 13 high risk groups were 75.56% and 73.33% The positive rate of HPVDNA by FQ-PCR (61.93%) was significantly lower than that of HC-II method (72.16%) (χ2 = 4.17, P <0.05) (2) The positive rates of HybriMax, HC-Ⅱ and FQ-PCR in patients with low cell abnormalities were 47.78%, 43.31% and 43.87%, respectively. There was no significant difference between HybriMax, The positive rates of HC-Ⅱ in detecting HPVDNA were 91.30% and 88.96%, respectively, with no significant difference (χ2 = 0.45, P> 0.05). The positive rates of HCT-PCR and FQ-PCR were 76.19% and 90.48% Although statistically significant difference was not statistically significant, but trends suggest that the clinical sensitivity of FQ-PCR may be lower than the HC-Ⅱ. Conclusion The HybriMax technique has good clinical sensitivity for detecting HPVDNA and has the advantages of simultaneous typing. It is worthy of clinical promotion.